> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS, LabCentral Agreement on Pharma/Biotech Startups
- URL: https://www.fdaweb.com/bms-labcentral-agreement-on-pharma-biotech-startups/
- Published: 2016-03-07T12:00:00.000Z
- Updated: 2026-09-15T02:41:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134979

> Bristol-Myers Squibb and LabCentral, a Cambridge, MA shared space and launch pad for life-sciences and biotech startups, have entered into an agreement under which Bristol-Myers Squibb has become a platinum sponsor and can nominate up to two startup companies per year to take up residence in the lab’s Kendall Square facilities. “Our residents who are working to move early-stage science from the lab bench toward clinical trials stand to gain valuable insights from regular interactions with Bristol-Myers Squibb mentors who are veterans of the process,” LabCentral co-founder and president **Johannes Fruehauf** is quoted in a release as saying. Last year, Bristol-Myers Squibb [announced](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fnews.bms.com%2Fpress-release%2Frd-news%2Fbristol-myers-squibb-expands-rd-presence-within-hubs-world-class-science-and-i&esheet=51294367&newsitemid=20160307005156&lan=en-US&anchor=announced&index=3&md5=6ecae6beb106970ad512439a07a1d6c3&ref=fdaweb.com) that it will launch a new state-of-the-art research site in Kendall Square, which is expected to open in early 2018.